ReviewJournal of innate immunity2013
Interferon-λs: special immunomodulatory agents and potential therapeutic targets.
Review in Journal of innate immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The role of IFNLR1 in modulating T cell infiltration and cancer progression in renal cell carcinoma.Journal of translational medicine · 2026Article
- High levels of nonblocking anti-interferon and anticytokine autoantibodies in individuals with mRNA vaccine-induced systemic allergic reactions.The journal of allergy and clinical immunology. Global · 2026Article
- Article
- Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication.Scientific reports · 2021Article
- Identification of novel blood biomarker panels to detect ischemic stroke in patients and their responsiveness to therapeutic intervention.Brain research · 2018Article
- Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese.Arthritis research & therapy · 2018Article
- Up-regulation of Kv1.3 channels by janus kinase 2.The Journal of membrane biology · 2015Article
- Interferon-λ: Inters Ferocity or Inter-Ferocities?Journal of innate immunity · 2015Article
- Interferon-λ1 suppresses invasion and enhances autophagy in human osteosarcoma cell.International journal of clinical and experimental medicine · 2015Article
- The Role of Interferon-λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases.Journal of innate immunity · 2015Review
- Effect of human interferon-λ1 recombinant adenovirus on a gastric cancer orthotopic transplantation model.Experimental and therapeutic medicine · 2014Article
- The bacterial pathogen Listeria monocytogenes and the interferon family: type I, type II and type III interferons.Frontiers in cellular and infection microbiology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon (IFN)-λs are a new addition to the old IFN family and share many similarities, such as antiviral and antiproliferative characteristics, with type I IFNs. IFN-λs also exhibit unique characteristics in immunomodulation. Accumulating studies have indicated the interactions between IFN-λs and immune cells, which lead to the regulation of the latter. IFN-λs can influence dendritic cells (DCs) and their product, IFN-λs-DCs, can then regulate the function of T cells. On the other hand, IFN-λs can also directly affect T cells through inhibition of the T helper 2 cell (Th2) responses. IFN-λs have varying immunomodulatory functions under different physiological conditions or in different organs and can inhibit tumor growth via regulation of the immune system. Diseases associated with IFN-λs include asthma, allergy, and systemic lupus erythematosus. In this review, we summarize the current knowledge of the biology of IFN-λs and their immunomodulatory function in relevant human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.